Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly’s Taltz Hits Mark in Phase III Inflammatory Study

Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for non-radiographic axial spondyloarthritis.

Read More »

Solid Biosciences shares plummet as gene therapy trial halted again

Shares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.

Read More »

AstraZeneca succeeds in treating lupus in late-stage study

AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.

Read More »

Daiichi Sankyo’s Hypertension Drug Hits Mark in Diabetic Nephropathy Trial

Tokyo-based Daiichi Sankyo’s ESAX-DN Phase III trial of esaxerenone met the primary endpoint in diabetic nephropathy.

Read More »

Roche Terminates Myostatin Inhibitor for DMD

A little more than one year after Pfizer terminated the company’s studies of PF-06252616 as a potential treatment for Duchenne muscular dystrophy, Swiss pharma giant Roche is following suit with the terminated development of RG6206.

Read More »

Abbott Announces Discovery of New Strain of HIV

A team of Abbott scientists identified a new subtype of the human immunodeficiency virus, called HIV-1 Group M, subtype L.

Read More »

Novartis arthritis drug falls short in challenge to global bestseller

A clinical trial fell short of producing statistical evidence that Novartis’ anti-inflammatory drug Cosentyx can beat the world’s best-selling medicine Humira in treating a type of arthritis.

Read More »

Breast Cancer: Steady Progress Being Made in New Treatments

For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.

Read More »

Novartis’ Zolgensma study halted by FDA amid safety questions

U.S. regulators halted a trial of Novartis’ Zolgensma treatment after an animal study raised safety concerns, in a setback for the drugmaker’s plan to expand the product’s use to older patients.

Read More »

Cancer drug combo meets late-stage trial goal

AstraZeneca Plc’s cancer drug Imfinzi in combination with chemotherapy and the company’s cancer medicine tremelimumab met the main goal of delaying progression of a form of lung cancer.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom